Regenxbio Inc (RGNX) Stock
Key stats
- Market cap
- $560.06M
- Price / Earnings ratio
- -2.9x
- EPS (TTM)
- -$3.21
- Volume
- Loading
- 52-week high
- $16.19
- 52-week low
- $5.46
Source: third-party data provider, as of November 13, 2026
Compare with RGNX
Recent news

Regenxbio (RGNX) Expected to Beat Earnings Estimates: Should You Buy?
Regenxbio (RGNX) Expected to Beat Earnings Estimates: Should You Buy?
RGNX

REGENXBIO Eyes Q4 Pivotal Readout for One-Time Wet AMD Gene Therapy
REGENXBIO Eyes Q4 Pivotal Readout for One-Time Wet AMD Gene Therapy
RGNX

Stocktwits Pharma Pulse: Moderna-Merck Cancer Vaccine Grabs Spotlight As Kidney-Cancer And MS Data Pour In
Stocktwits Pharma Pulse: Moderna-Merck Cancer Vaccine Grabs Spotlight As Kidney-Cancer And MS Data Pour In
RGNX

Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of REGENXBIO Inc. (RGNX)
Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of REGENXBIO Inc. (RGNX)
RGNX
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 61.07
- MACD 12/26/9
- 0.07
- EMA 9 of MACD
- -0.10
- MACD histogram
- 0.17
- SMA 50
- $7.72
- Price above SMA 50
- EMA 50
- $7.90
- Price above EMA 50
- SMA 200
- $8.91
- Price below SMA 200
- EMA 200
- $9.30
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 3 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of -$0.89 for this quarter. The company has not yet shared when it is announcing earnings.
Source: third-party data provider
Latest news

Regenxbio (RGNX) Expected to Beat Earnings Estimates: Should You Buy?
Regenxbio (RGNX) Expected to Beat Earnings Estimates: Should You Buy?
RGNX

REGENXBIO Eyes Q4 Pivotal Readout for One-Time Wet AMD Gene Therapy
REGENXBIO Eyes Q4 Pivotal Readout for One-Time Wet AMD Gene Therapy
RGNX

Stocktwits Pharma Pulse: Moderna-Merck Cancer Vaccine Grabs Spotlight As Kidney-Cancer And MS Data Pour In
Stocktwits Pharma Pulse: Moderna-Merck Cancer Vaccine Grabs Spotlight As Kidney-Cancer And MS Data Pour In
RGNX

Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of REGENXBIO Inc. (RGNX)
Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of REGENXBIO Inc. (RGNX)
RGNX

RGNX Stock Slumps 25% on FDA Clinical Hold for RGX-121 Gene Therapy
RGNX Stock Slumps 25% on FDA Clinical Hold for RGX-121 Gene Therapy
RGNX

RGNX Stock On Track For Worst Day In Over Three Months — BofA Says Buy Despite ‘Disappointing’ FDA Hold On Gene Therapy
RGNX Stock On Track For Worst Day In Over Three Months — BofA Says Buy Despite ‘Disappointing’ FDA Hold On Gene Therapy
RGNX

Why Did RGNX Stock Crash Today?
Why Did RGNX Stock Crash Today?
RGNX

FDA places clinical hold on Regenxbio's gene therapy for Hunter Syndrome
FDA places clinical hold on Regenxbio's gene therapy for Hunter Syndrome
RGNX

REGENXBIO Q2 Earnings Call Highlights
REGENXBIO Q2 Earnings Call Highlights
RGNX

Regenxbio (RGNX) Beats Q2 Earnings and Revenue Estimates
Regenxbio (RGNX) Beats Q2 Earnings and Revenue Estimates
RGNX
News tone: automated (AI) classification of the article's content, not a price prediction.
About Regenxbio Inc
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that the Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Curran M. Simpson M.S. | President, CEO & Director | 1962 |
| Mr. Mitchell Chan M.B.A. | Executive VP & CFO | 1981 |
| Mr. Patrick J. Christmas II, J.D. | Executive VP & Chief Strategy and Legal Officer | 1971 |
| Dr. Stephen Pakola M.D. | Executive VP & Chief Medical Officer | 1969 |
| Mr. Craig Malzahn | Executive VP of Product Development & CTO | 1973 |
| Dr. Olivier Danos Ph.D. | Executive VP & Chief Scientific Officer | 1958 |
| Ms. Shiva G. Fritsch | Chief Communications & People Officer | — |
| Dr. Ram Palanki Pharm.D. | Executive VP & Chief Commercial Officer | 1976 |
| Ms. Nina Hunter | SVP of Global Regulatory Strategy and Quality | — |
| Dr. Jahannaz Dastgir D.O. | Clinical Development Lead | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 61.07
- MACD 12/26/9
- 0.07
- EMA 9 of MACD
- -0.10
- MACD histogram
- 0.17
- SMA 50
- $7.72
- Price above SMA 50
- EMA 50
- $7.90
- Price above EMA 50
- SMA 200
- $8.91
- Price below SMA 200
- EMA 200
- $9.30
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
3 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $21.00
- Average
- $24.00
- High
- $29.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | +0.9 | +7.9 | ||||||||||
| 2022 | -23.1 | -2.3 | +25.5 | -20.8 | -26.0 | +16.6 | +22.3 | -5.0 | -11.9 | -2.1 | -3.4 | -3.7 |
| 2023 | +4.3 | -5.2 | -21.7 | -0.1 | -14.3 | +7.7 | -5.0 | -7.6 | -9.2 | -19.8 | +37.6 | -8.7 |
| 2024 | -32.8 | +37.5 | -0.6 | -28.7 | -11.4 | -20.7 | +28.7 | -8.2 | -7.5 | -15.9 | +12.9 | -22.7 |
| 2025 | +2.7 | -16.0 | +20.8 | +42.2 | -10.0 | -20.7 | +3.4 | +9.0 | +5.8 | +30.7 | +11.7 | +14.3 |
| 2026 | -17.8 | -16.1 | -9.3 | +3.9 | -23.1 | +67.8 | -26.0 | -4.6 | -19.2 | -3.0 | +18.3 |



